Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Regeneron cuts White House pricing deal, offers new gene therapy for free

The White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Latest news

500,000 patients’ data for sale online after UK Biobank breach

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.

ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

Cumberland to sell drug portfolio to Apotex for $100m

Under the agreement, Apotex will acquire Cumberland's portfolio of branded medicines for cash.

ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV

Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon.

Medicare weight loss drug pilot on ice as insurers decline to contribute

The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 December 2027.